세계의 카테터 및 Active Implantable CDMO 시장 : 서비스 카테고리, 최종 사용자 및 지역별 예측(-2032년)

Global Catheters and Active Implantable CDMO Market Research Report Information by Service Category (Catheters, Active Implantable Devices, Endoscopy Devices, and Others), By End-Users (Medical Device OEM Companies, Academic and Research Institutes, and Government Agencies) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) -Market Forecast Till 2032

Market Overview

The Catheters and Active Implantable CDMO Market was valued at USD 6.92 billion in 2023. The market is expected to increase from USD 7.49 billion in 2024 to USD 18.8 billion by 2032, with a compound annual growth rate (CAGR) of 10.82% for the forecast period (2024-2032).

The market expansion is being driven by increased strategic initiatives connected with catheters and active implantable CDMO, as well as increased production outsourcing.

Growing initiatives are promoting innovation and enhancing market accessibility, significantly boosting the global market for catheters and active implanted CDMOs. Strategic mergers and acquisitions enable organizations to offer comprehensive solutions and accelerate product development by pooling resources and knowledge. Simultaneously, the use of advanced catheters and implantable devices is increasing as a result of increased investments in healthcare infrastructure, particularly in emerging nations, and a growing preference for less intrusive procedures.

Market Segment insights

The Catheters and Active Implantable CDMO Market is divided into three service segments: catheters, active implantable devices, and endoscopy devices.

The Catheters and Active Implantable CDMO Market is divided into three end user segments: medical device OEM firms, academic and research organizations, and government agencies.

Regional insights

North America held the biggest market share in 2023 and is expected to grow over the forecast period. However, Asia-Pacific is expected to develop at the fastest CAGR over the forecast period.

The Active Implantable CDMO market in North America is expanding rapidly, owing to technical developments, a favorable regulatory environment, and rising healthcare demands. Furthermore, the market is driven by sophisticated healthcare infrastructure and significant investment in R&D, which allows for the development of cutting-edge implantable devices. Furthermore, potential for development into emerging countries, the rise of customized treatment, and the demand for minimally invasive solutions offer paths for growth.

The Americas region is followed by Europe, which is further divided into Germany, France, the United Kingdom, Italy, Spain, and the Rest of Europe. The Active Implantable CDMO market in Europe has great growth potential, driven by technological advancements and rising healthcare demands. Implantable device technology improvements, such as next-generation cardiac pacemakers, neurostimulators, and insulin pumps, are driving up demand for specialized manufacturing capabilities. The rising frequency of chronic diseases, fueled by an aging population, heightens the demand for complex, high-quality implantable treatments.

Asia-Pacific is predicted to show significant growth and is projected to be the fastest growing region throughout the projection period. Several important drivers are driving robust growth. Rapid improvements in medical technology, as well as increased investment in healthcare infrastructure in nations such as China, India, and Japan, are driving demand for advanced implantable devices. The increased prevalence of chronic diseases, diabetes, and an aging population increase the demand for novel remedies.

Major Players

Major competitors in the Catheters and Active Implantable CDMO Market include Integer Holdings Corporation (US), Cirtec (US), Biomerics (US), Switchback Medical (US), Velentium LLC (US), Heraeus Group (Germany), Zeus Company LLC (US), Veranex (US), Freudenberg Medical (US), and Medeologix (Taiwan).

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

• 3.1 OVERVIEW
• 3.2 DATA FLOW
  • 3.2.1 Data Mining Process
• 3.3 PURCHASED DATABASE:
• 3.4 SECONDARY SOURCES:
  • 3.4.1 Secondary Research data flow:
• 3.5 PRIMARY RESEARCH:
  • 3.5.1 Primary Research DATA FLOW:
  • 3.5.2 Primary Research: Number of Interviews conducted
  • 3.5.3 Primary Research: Regional Coverage
• 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
  • 3.6.1 Revenue Analysis Approach
• 3.7 DATA FORECASTING
  • 3.7.1 Data forecasting Technique
• 3.8 DATA MODELING
  • 3.8.1 microeconomic factor analysis:
  • 3.8.2 Data modeling:
• 3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

• 4.1 INTRODUCTION
• 4.2 DRIVERS
  • 4.2.1 Increasing strategic initiatives associated with Catheters and Active Implantable CDMO
  • 4.2.2 Increased Outsourcing of Manufacturing
• 4.3 RESTRAINTS
  • 4.3.1 Stringent regulatory Policies
• 4.4 OPPORTUNITY
  • 4.4.1 Growing geriatric population across the globe
  • 4.4.2 FACILITY EXPANSION by Contract Development Manuacturing Organization

5 MARKET FACTOR ANALYSIS

• 5.1 PORTER'S FIVE FORCES MODEL
  • 5.1.1 Threat of New Entrants
  • 5.1.2 Bargaining Power of Suppliers
  • 5.1.3 Threat of Substitutes
  • 5.1.4 Bargaining Power of Buyers
  • 5.1.5 Intensity of Rivalry
• 5.2 IMPACT OF COVID-19 ON THE GLOBAL CATHETERS AND ACTIVE IMPLANTABLE CDMO MARKET
• 5.3 TRENDS IN CDMO FOR CATHETERS AND ACTIVE IMPLANTABLE CDMO MARKET
  • 5.3.1 Shifting Focus of Medical Device CDMOs to Improve Capabilities

6 GLOBAL CATHETERS AND ACTIVE IMPLANTABLE CDMO MARKET, BY SERVICE CATEGORY

• 6.1 OVERVIEW
• 6.2 CATHETERS
  • 6.2.1 Cardiac Catheters
  • 6.2.2 Urology Catheters
  • 6.2.3 Neurovascular Catheters
  • 6.2.4 Others
• 6.3 ACTIVE IMPLANTABLE DEVICES
  • 6.3.1 Neuromodulation Devices
    • 6.3.1.1 Spinal Cord Stimulators
    • 6.3.1.2 Deep Brain Stimulators
    • 6.3.1.3 Others
  • 6.3.2 Structural Heart Devices
    • 6.3.2.1 Valve Implants
    • 6.3.2.2 Stents & Shunts
    • 6.3.2.3 Others
  • 6.3.3 Heart Failure Devices
    • 6.3.3.1 Percutaneous Left Ventricular Assist Device (LVAD)
    • 6.3.3.2 Percutaneous Right Ventricular Support Devices (RVAD)
    • 6.3.3.3 Others
  • 6.3.4 Urology Implantable Devices
  • 6.3.5 Others
• 6.4 ENDOSCOPY DEVICES
• 6.5 OTHERS

7 GLOBAL CATHETERS AND ACTIVE IMPLANTABLE CDMO MARKET, BY END USER

• 7.1 OVERVIEW
• 7.2 MEDICAL DEVICE OEM COMPANIES
• 7.3 ACADEMIC AND RESEARCH INSTITUTES
• 7.4 GOVERNMENT AGENCIES

8 GLOBAL CATHETERS AND ACTIVE IMPLANTABLE CDMO MARKET, BY REGION

• 8.1 OVERVIEW
• 8.2 NORTH AMERICA
  • 8.2.1 US
  • 8.2.2 Canada
• 8.3 EUROPE
  • 8.3.1 Germany
  • 8.3.2 France
  • 8.3.3 UK
  • 8.3.4 Italy
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 ASIA-PACIFIC
  • 8.4.1 China
  • 8.4.2 India
  • 8.4.3 Japan
  • 8.4.4 South Korea
  • 8.4.5 Australia
  • 8.4.6 Rest of Asia-Pacific
• 8.5 REST OF THE WORLD
  • 8.5.1 Middle East & Africa
  • 8.5.2 South America

9 COMPETITIVE LANDSCAPE

• 9.1 INTRODUCTION
• 9.2 MARKET SHARE ANALYSIS,
• 9.3 COMPETITOR DASHBOARD
• 9.4 PUBLIC PLAYERS STOCK SUMMARY
• 9.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
• 9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 9.6.1 Facility expansion
  • 9.6.2 Acquisition
  • 9.6.3 Partnership

10 COMPANY PROFILES

• 10.1 INTEGER HOLDINGS CORPORATION
  • 10.1.1 COMPANY OVERVIEW
  • 10.1.2 FINANCIAL OVERVIEW
  • 10.1.3 productS OFFERED
  • 10.1.4 KEY DEVELOPMENTS
  • 10.1.5 SWOT ANALYSIS
  • 10.1.6 KEY STRATEGIES
• 10.2 CIRTEC
  • 10.2.1 COMPANY OVERVIEW
  • 10.2.2 FINANCIAL OVERVIEW
  • 10.2.3 PRODUCT OFFERED
  • 10.2.4 KEY DEVELOPMENTS
  • 10.2.5 SWOT ANALYSIS
  • 10.2.6 KEY STRATEGIES
• 10.3 BIOMERICS
  • 10.3.1 COMPANY OVERVIEW
  • 10.3.2 FINANCIAL OVERVIEW
  • 10.3.3 PRODUCTS OFFERED
  • 10.3.4 KEY DEVELOPMENTS
  • 10.3.5 KEY STRATEGIES
• 10.4 SWITCHBACK MEDICAL
  • 10.4.1 COMPANY OVERVIEW
  • 10.4.2 FINANCIAL OVERVIEW
  • 10.4.3 PRODUCTS OFFERED
  • 10.4.4 KEY DEVELOPMENTS
  • 10.4.5 SWOT ANALYSIS
  • 10.4.6 KEY STRATEGIES
• 10.5 VELENTIUM LLC
  • 10.5.1 COMPANY OVERVIEW
  • 10.5.2 FINANCIAL OVERVIEW
  • 10.5.3 PRODUCTS OFFERED
  • 10.5.4 KEY DEVELOPMENTS
  • 10.5.5 KEY STRATEGIES
• 10.6 HERAEUS GROUP
  • 10.6.1 COMPANY OVERVIEW
  • 10.6.2 FINANCIAL OVERVIEW
  • 10.6.3 PRODUCTS OFFERED
  • 10.6.4 KEY DEVELOPMENTS
  • 10.6.5 SWOT ANALYSIS
  • 10.6.6 KEY STRATEGIES
• 10.7 ZEUS COMPANY LLC
  • 10.7.1 COMPANY OVERVIEW
  • 10.7.2 FINANCIAL OVERVIEW
  • 10.7.3 PRODUCTS OFFERED
  • 10.7.4 KEY DEVELOPMENTS
  • 10.7.5 SWOT ANALYSIS
  • 10.7.6 KEY STRATEGIES
• 10.8 VERANEX
  • 10.8.1 COMPANY OVERVIEw
  • 10.8.2 FINANCIAL OVERVIEW
  • 10.8.3 Product OFFERed
  • 10.8.4 KEY DEVELOPMENTS
  • 10.8.5 KEY STRATEGIES
• 10.9 FREUDENBERG MEDICAL
  • 10.9.1 COMPANY OVERVIEW
  • 10.9.2 FINANCIAL OVERVIEW
  • 10.9.3 PRODUCTS OFFERED
  • 10.9.4 KEY DEVELOPMENTS
  • 10.9.5 KEY STRATEGIES
• 10.10 MEDEOLOGIX
  • 10.10.1 COMPANY OVERVIEW
  • 10.10.2 FINANCIAL OVERVIEW
  • 10.10.3 PRODUCTS OFFERED
  • 10.10.4 KEY DEVELOPMENTS
  • 10.10.5 KEY STRATEGIES
• 10.11 DATA CITATIONS